Clinical Trial

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 28, 2024 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-28; most recent amendment 2024-10-24.
Status change: Not Yet Recruiting → Recruiting 2024-10-24
Trial Details
NCT Number NCT05927428
Lead Sponsor BRIM Biotechnology Inc.
Conditions Neurotrophic Keratitis
Enrollment 12 participants
Start Date 2024-07-31
Primary Completion 2025-08-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-28